share_log

Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral, Raises Price Target to $32

Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral, Raises Price Target to $32

高盛將Agios PharmPharmticals評級上調至中性,將目標價上調至32美元
Benzinga Real-time News ·  2022/11/17 08:26

Goldman Sachs analyst Salveen Richter upgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Sell to Neutral and raises the price target from $17 to $32.

高盛分析師Salveen Richter將Agios PharmPharmticals(納斯達克:AGIO)評級從賣出上調至中性,並將目標價從17美元上調至32美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論